These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 19430168)

  • 1. Use of an intravenous microdose of 14C-labeled drug and accelerator mass spectrometry to measure absolute oral bioavailability in dogs; cross-comparison of assay methods by accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
    Miyaji Y; Ishizuka T; Kawai K; Hamabe Y; Miyaoka T; Oh-hara T; Ikeda T; Kurihara A
    Drug Metab Pharmacokinet; 2009; 24(2):130-8. PubMed ID: 19430168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs.
    Lappin G; Kuhnz W; Jochemsen R; Kneer J; Chaudhary A; Oosterhuis B; Drijfhout WJ; Rowland M; Garner RC
    Clin Pharmacol Ther; 2006 Sep; 80(3):203-15. PubMed ID: 16952487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers.
    Sarapa N; Hsyu PH; Lappin G; Garner RC
    J Clin Pharmacol; 2005 Oct; 45(10):1198-205. PubMed ID: 16172185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming bioanalytical challenges in an Onglyza(®) intravenous [(14)C]microdose absolute bioavailability study with accelerator MS.
    Xu XS; Dueker SR; Christopher LJ; Lohstroh PN; Keung CF; Cao KK; Bonacorsi SJ; Cojocaru L; Shen JX; Humphreys WG; Stouffer B; Arnold ME
    Bioanalysis; 2012 Aug; 4(15):1855-70. PubMed ID: 22943617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A convenient strategy to overcome interference in LC-MS/MS analysis: Application in a microdose absolute bioavailability study.
    Yuan L; Huang C; Liu-Kreyche P; Voronin K; Fancher RM; Allentoff A; Zheng N; Iyer R; Zhu L; Pillutla R; Ji QC
    J Pharm Biomed Anal; 2019 Feb; 165():198-206. PubMed ID: 30553110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose.
    Roosendaal J; Groenland SL; Rosing H; Lucas L; Venekamp N; Nuijen B; Huitema ADR; Beijnen JH; Steeghs N
    Eur J Clin Pharmacol; 2020 Aug; 76(8):1075-1082. PubMed ID: 32430518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precision and accuracy in the quantitative analysis of biological samples by accelerator mass spectrometry: application in microdose absolute bioavailability studies.
    Gao L; Li J; Kasserra C; Song Q; Arjomand A; Hesk D; Chowdhury SK
    Anal Chem; 2011 Jul; 83(14):5607-16. PubMed ID: 21627104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers.
    Lappin G; Shishikura Y; Jochemsen R; Weaver RJ; Gesson C; Brian Houston J; Oosterhuis B; Bjerrum OJ; Grynkiewicz G; Alder J; Rowland M; Garner C
    Eur J Pharm Sci; 2011 Jun; 43(3):141-50. PubMed ID: 21540108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calculation and mitigation of isotopic interferences in liquid chromatography-mass spectrometry/mass spectrometry assays and its application in supporting microdose absolute bioavailability studies.
    Gu H; Wang J; Aubry AF; Jiang H; Zeng J; Easter J; Wang JS; Dockens R; Bifano M; Burrell R; Arnold ME
    Anal Chem; 2012 Jun; 84(11):4844-50. PubMed ID: 22540405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity-based analytical approaches to support human absolute bioavailability studies.
    Xu XS; Jiang H; Christopher LJ; Shen JX; Zeng J; Arnold ME
    Bioanalysis; 2014 Feb; 6(4):497-504. PubMed ID: 24568352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a
    van Andel L; Rosing H; Zhang Z; Hughes L; Kansra V; Sanghvi M; Tibben MM; Gebretensae A; Schellens JHM; Beijnen JH
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):39-46. PubMed ID: 29043410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microdose pharmacogenetic study of ¹⁴C-tolbutamide in healthy subjects with accelerator mass spectrometry to examine the effects of CYP2C9∗3 on its pharmacokinetics and metabolism.
    Ikeda T; Aoyama S; Tozuka Z; Nozawa K; Hamabe Y; Matsui T; Kainuma M; Hasegawa S; Maeda K; Sugiyama Y
    Eur J Pharm Sci; 2013 Jul; 49(4):642-8. PubMed ID: 23727057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of microdosing strategies for studies in preclinical drug development: demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range.
    Sandhu P; Vogel JS; Rose MJ; Ubick EA; Brunner JE; Wallace MA; Adelsberger JK; Baker MP; Henderson PT; Pearson PG; Baillie TA
    Drug Metab Dispos; 2004 Nov; 32(11):1254-9. PubMed ID: 15286054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microdose study of 14C-acetaminophen with accelerator mass spectrometry to examine pharmacokinetics of parent drug and metabolites in healthy subjects.
    Tozuka Z; Kusuhara H; Nozawa K; Hamabe Y; Ikushima I; Ikeda T; Sugiyama Y
    Clin Pharmacol Ther; 2010 Dec; 88(6):824-30. PubMed ID: 21048707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accelerator mass spectrometry analysis of background (14)C-concentrations in human blood: aiming at reference data for further microdosing studies.
    Minamimoto R; Hamabe Y; Miyaoka T; Hara T; Yoshida K; Oka T; Inoue T
    Ann Nucl Med; 2008 Dec; 22(10):883-9. PubMed ID: 19142707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morphine brain pharmacokinetics at very low concentrations studied with accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
    Sadiq MW; Salehpour M; Forsgard N; Possnert G; Hammarlund-Udenaes M
    Drug Metab Dispos; 2011 Feb; 39(2):174-9. PubMed ID: 21059857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry.
    Balani SK; Nagaraja NV; Qian MG; Costa AO; Daniels JS; Yang H; Shimoga PR; Wu JT; Gan LS; Lee FW; Miwa GT
    Drug Metab Dispos; 2006 Mar; 34(3):384-8. PubMed ID: 16326814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and metabolism of the new thromboxane A2 receptor antagonist ramatroban in animals. 1st communication: absorption, concentrations in plasma, metabolism, and excretion after single administration to rats and dogs.
    Boberg M; Ahr HJ; Beckermann B; Bühner K; Siefert HM; Steinke W; Wünsche C; Hirayama M
    Arzneimittelforschung; 1997 Aug; 47(8):928-38. PubMed ID: 9296279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A combined accelerator mass spectrometry-positron emission tomography human microdose study with 14C- and 11C-labelled verapamil.
    Wagner CC; Simpson M; Zeitlinger M; Bauer M; Karch R; Abrahim A; Feurstein T; Schütz M; Kletter K; Müller M; Lappin G; Langer O
    Clin Pharmacokinet; 2011 Feb; 50(2):111-20. PubMed ID: 21142292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of 2'-deoxy-2'-β-fluoro-4'-azidocytidine in rat and dog plasma using liquid chromatography-quadrupole time-of-flight and liquid chromatography-triple quadrupole mass spectrometry: Application to bioavailability and pharmacokinetic studies.
    Peng Y; Cheng T; Dong L; Zhang Y; Chen X; Jiang J; Zhang J; Guo X; Guo M; Chang J; Wang Q
    J Pharm Biomed Anal; 2014 Sep; 98():379-86. PubMed ID: 24999865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.